Anti-Aging

Study: Anti-Aging Products and Self Esteem
May 23, 2022

A Portuguese study examined the association between the use of anti-aging products and the self-esteem of the women who used them.

The Mainstream Patient: May 9
May 09, 2022

This week's edition of the Mainstream Patients features stories about treating scars, jojoba oil for skin, and more.

Aesthetics in Skin of Color: Pearls and Precautions
May 05, 2022

Aging in skin of color is less about wrinkling and more about fat loss.

New Cosmeceutical Ingredients
May 03, 2022

“Medical literature from India and the Middle East is full of reports of success in treating postinflammatory hyperpigmentation and melasma with topical tranexamic acid, but properly powered, well-controlled studies are still lacking.”

The Future of Aesthetics: Natural is Back in
May 01, 2022

Ilanit Samuels, PA-C, talks the future of aesthetics and the trends she sees while treating her patients at the Florida Society of Dermatology Physician Assistants 2022 New Wave Dermatology Conference.

PAs Tackle Injectables
April 30, 2022

IIanit Samuels, PA-C, of Illy Aesthetics, discusses the importance of thorough injectable training.

The Collaboration Behind Injections
April 30, 2022

Tanya Patron, PA-C, the owner and founder of the Selfie Aesthetic, gave an important talk on neurotoxins at the 2022 New Wave Dermatology Conference in Coral Gables, Florida.

Socially Sensitive Discussions Needed on Skin Lighteners
April 29, 2022

Theodore Rosen, MD, highlights the need for communication with patients about the potential harm of using skin-whiteners.

Meet the Aesthetics Expert with Dr. Will Kirby: Collin M. Blattner, DO, FAAD
April 28, 2022

In this month’s “Meet the Aesthetic Expert” column, Will Kirby, DO, FAOCD, talks with Collin M. Blattner, DO, FAAD, about perspective-changing complications, the future of aesthetic conferences, and the importance of allied health care providers.

FDA Accepts BLA Resubmission for DAXI Injections
April 22, 2022

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.